Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

Tumor marker response to SARS-CoV-2 infection among patients with cancer.

Publication ,  Journal Article
Gunn, AH; Tashie, C; Wolf, S; Troy, JD; Zafar, Y
Published in: Cancer Med
July 2022

BACKGROUND: Inflammatory responses from benign conditions can cause non-cancer-related elevations in tumor markers. The severe acute respiratory coronavirus 2 (SARS-CoV-2) induces a distinct viral inflammatory response, resulting in coronavirus disease 2019 (COVID-19). Clinical data suggest carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA 19-9), and cancer antigen 125 (CA 125) levels might rise in patients with COVID-19. However, available data excludes cancer patients, so little is known about the effect of COVID-19 on tumor markers among cancer patients. METHODS: We conducted a case series and identified patients with a positive SARS-CoV-2 PCR test, diagnosis of a solid tumor malignancy, and a CEA, CA 19-9, CA 125, or CA 27-29 laboratory test. Cancer patients with documented COVID-19 infection and at least one pre- and two post-infection tumor marker measurements were included. We abstracted the electronic health record for demographics, cancer diagnosis, treatment, evidence of cancer progression, date and severity of COVID-19 infection, and tumor marker values. RESULTS: Seven patients were identified with a temporary elevation of tumor marker values during the post-COVID-19 period. Elevation in tumor marker occurred within 56 days of COVID-19 infection for all patients. Tumor markers subsequently decreased at the second time point in the post-infectious period among all patients. CONCLUSION: We report temporary elevations of cancer tumor markers in the period surrounding COVID-19 infection. To our knowledge this is the first report of this phenomenon in cancer patients and has implications for clinical management and future research.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Cancer Med

DOI

EISSN

2045-7634

Publication Date

July 2022

Volume

11

Issue

14

Start / End Page

2865 / 2872

Location

United States

Related Subject Headings

  • SARS-CoV-2
  • Pneumonia
  • Neoplasms
  • Humans
  • Carcinoembryonic Antigen
  • COVID-19
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 0601 Biochemistry and Cell Biology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gunn, A. H., Tashie, C., Wolf, S., Troy, J. D., & Zafar, Y. (2022). Tumor marker response to SARS-CoV-2 infection among patients with cancer. Cancer Med, 11(14), 2865–2872. https://doi.org/10.1002/cam4.4646
Gunn, Alexander H., Carolyn Tashie, Steven Wolf, Jesse D. Troy, and Yousuf Zafar. “Tumor marker response to SARS-CoV-2 infection among patients with cancer.Cancer Med 11, no. 14 (July 2022): 2865–72. https://doi.org/10.1002/cam4.4646.
Gunn AH, Tashie C, Wolf S, Troy JD, Zafar Y. Tumor marker response to SARS-CoV-2 infection among patients with cancer. Cancer Med. 2022 Jul;11(14):2865–72.
Gunn, Alexander H., et al. “Tumor marker response to SARS-CoV-2 infection among patients with cancer.Cancer Med, vol. 11, no. 14, July 2022, pp. 2865–72. Pubmed, doi:10.1002/cam4.4646.
Gunn AH, Tashie C, Wolf S, Troy JD, Zafar Y. Tumor marker response to SARS-CoV-2 infection among patients with cancer. Cancer Med. 2022 Jul;11(14):2865–2872.
Journal cover image

Published In

Cancer Med

DOI

EISSN

2045-7634

Publication Date

July 2022

Volume

11

Issue

14

Start / End Page

2865 / 2872

Location

United States

Related Subject Headings

  • SARS-CoV-2
  • Pneumonia
  • Neoplasms
  • Humans
  • Carcinoembryonic Antigen
  • COVID-19
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 0601 Biochemistry and Cell Biology